Leqembi (Lecanemab)

Lecanemab is a humanized monoclonal antibody that selectively binds to soluble aggregated amyloid‑beta protofibrils. By targeting these aggregates, it promotes their clearance through immune mechanisms, thereby lowering overall amyloid plaque load in the brain.

The dosing regimen for Leqembi is determined by the prescribing clinician based on the patient’s clinical status, weight, and laboratory findings. The prescriber sets the infusion schedule and any dose adjustments.

Safety data for lecanemab in pregnancy and lactation are limited. The product carries an unknown pregnancy category, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant.

To request Leqembi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping (including cold‑chain logistics), and import documentation.

Leqembi belongs to the class of amyloid‑targeting monoclonal antibodies, similar to aducanumab and donanemab. Compared with earlier agents, lecanemab has shown a favorable safety profile with lower rates of severe ARIA, while providing comparable reductions in amyloid burden.

Leqembi must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution before infusion.

Leqembi is supplied as an intravenous solution for infusion. It is administered by a qualified healthcare professional through a controlled IV infusion, typically over a period defined by the prescribing physician.

The most serious risks include amyloid‑related imaging abnormalities (ARIA‑E or ARIA‑H), which can manifest as brain edema or microhemorrhages, and severe hypersensitivity reactions such as anaphylaxis. Regular MRI monitoring is recommended to detect ARIA early.

Leqembi is contraindicated in patients with a history of severe hypersensitivity to lecanemab or any of its excipients, and in those with uncontrolled bleeding disorders or who are receiving high‑dose anticoagulation where the risk of intracerebral hemorrhage is deemed unacceptable.